BOLT trades 102.9% below Wall Street's consensus target of $7.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BOLT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, Bolt Biotherapeutics, Inc. (BOLT) has a Wall Street consensus price target of $7.00, based on estimates from 8 covering analysts. With the stock currently trading at $3.45, this represents a potential upside of +102.9%. The company has a market capitalization of $7M.
Analyst price targets range from a low of $7.00 to a high of $7.00, representing a 0% spread in expectations. The median target of $7.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 3 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, BOLT trades at a trailing P/E of -0.2x. Analysts expect EPS to grow -14.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RCUSArcus Biosciences, Inc. | $3.1B | $24.44 | $40.00 | +63.7% | Buy | — | 18 |
 AGENAgenus Inc. | $348M | $8.36 | $25.00 | +199.0% | Buy | 31.3x | 11 |
 IMVTImmunovant, Inc. | $6.9B | $33.62 | $40.00 | +19.0% | Buy | — | 23 |
 TGTXTG Therapeutics, Inc. | $8.3B | $54.29 | $80.50 | +48.3% | Buy | 55.8x | 13 |
 SNDXSyndax Pharmaceuticals, Inc. | $1.6B | $17.60 | $36.67 | +108.4% | Buy | — | 22 |
 NKTRNektar Therapeutics | $1.4B | $43.58 | $146.00 | +235.0% | Buy | — | 33 |
 FATEFate Therapeutics, Inc. | $270M | $2.32 | $5.63 | +142.7% | Buy | — | 31 |
 ALNYAlnylam Pharmaceuticals, Inc. | $29.3B | $219.72 | $347.33 | +58.1% | Buy | 33.0x | 52 |
 XNCRXencor, Inc. | $1.8B | $24.84 | $34.40 | +38.5% | Buy | — | 28 |
 MGNXMacroGenics, Inc. | $228M | $3.58 | $6.00 | +67.6% | Buy | — | 22 |
Quick answers to the most common questions about buying BOLT stock.
The consensus Wall Street price target for BOLT is $7, representing 102.9% upside from the current price of $3.45. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BOLT has a consensus rating of "Hold" based on 8 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $7 implies 102.9% upside from current levels.
BOLT's current price is $3.45 with a consensus target of $7 (102.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $7 for BOLT, while the most conservative target is $7. The consensus of $7 represents the median expectation. These targets typically reflect 12-month expectations.
BOLT is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BOLT stock forecast based on 8 Wall Street analysts shows a consensus price target of $7, with estimates ranging from $7 (bear case) to $7 (bull case). The median consensus rating is "Hold".
Wall Street analysts are very optimistic on BOLT, with a "Hold" consensus rating and $7 price target (102.9% upside). 3 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BOLT analyst price targets range from $7 to $7, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $7 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.